Lucia Del Vecchio

Dr. Lucia Del Vecchio

Department of Nephrology and Dialysis, ASST Lariana, 22100 Como, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Nature Clinical Practice Nephrology
Verified
Journal Article
Closed access
Lucia Del VecchioLucia Del Vecchio
Lucia Del Vecchio
MPMirella Procaccio
Mirella Procaccio
SVSara Viganò
Sara Viganò
DCDaniele Cusi
Daniele Cusi

7 August 2021 in Drugs
Verified
Journal Article
Closed access
PDF file
Lucia Del VecchioLucia Del Vecchio
Lucia Del Vecchio
ABAngelo Beretta
Angelo Beretta
CJCarlo Jovane
Carlo Jovane
SPSilvia Peiti
Silvia Peiti
SGSimonetta Genovesi
Simonetta Genovesi

18 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Lucia Del VecchioLucia Del Vecchio
Lucia Del Vecchio
RMRoberto Minutolo
Roberto Minutolo
Anemia is a well-known consequence of chronic kidney disease (CKD); it is mainly due to a relative insufficiency of erythropoietin synthesis by the failing kidneys. Over the years, the combination of erythropoiesis stimulating agents (ESA) and iron has become the standard of care of anemia. All ESAs effectively increase hemoglobin (Hb) levels in a substantial percentage of patients. However, in the last decade, their use has been surrounded by safety issues in increased cardiovascular risk, especially when used at high doses in inflamed and hyporesponsive patients. This has led to the definition of a more cautious Hb target. Iron deficiency is very frequent in CKD patients, with a higher frequency in non-dialysis patients. Traditionally, iron supplementation is mostly used as supportive therapy for anemia control. However, the concept is growing that intravenous iron therapy per se could be beneficial in the presence of heart failure. A new class of drugs, prolyl hydroxylase domain (PHD) inhibitors (PHD inhibitors) is becoming available for the treatment of anemia in CKD patients. Theoretically, these agents have a number of advantages, the main ones being that of stimulating the synthesis of endogenous erythropoietin and increasing iron availability. The impact of their future use in clinical practice is still to be defined. Another possible strategy could be targeting serum hepcidin and its related pathways. This possibility is fascinating from the scientific point of view, but at present its development phase is still far from clinical application.

13 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Lucia Del VecchioLucia Del Vecchio
Lucia Del Vecchio
MAMarco Allinovi
Marco Allinovi
PRPaolo Rocco
Paolo Rocco
Bruno BRANDOBruno BRANDO
Bruno BRANDO
Rituximab is a chimeric anti-CD20 monoclonal antibody. It acts mainly through complement-dependent cytotoxicity on B cells expressing the CD20 marker. In this review, we analyse the efficacy and possible pitfalls of rituximab to treat nephrotic syndromes by taking into account pharmacological considerations and CD19 marker testing utility. Despite the fact that the drug has been in use for years, efficacy and treatment schedules in adults with nephrotic syndrome are still a matter of debate. Clinical trials have proven the efficacy and safety of rituximab in idiopathic membranous nephropathy. Data from observational studies also showed the efficacy of rituximab in minimal change disease and focal segmental glomerulosclerosis. Rituximab use is now widely recommended by new Kidney Disease Improved Outcome (KDIGO) guidelines in membranous nephropathy and in frequent-relapsing, steroid-dependent minimal change disease or focal segmental glomerulosclerosis. However, rituximab response has a large interindividual variability. One reason could be that rituximab is lost in the urine at a higher extent in patients with nonselective nephrotic proteinuria, exposing patients to different rituximab plasma levels. Moreover, the association between CD19+ levels and clinical response or relapses is not always present, making the use of this marker in clinical practice complex. High resolution flow cytometry has increased the capability of detecting residual CD19+ B cells. Moreover, it can identify specific B-cell subsets (including IgG-switched memory B cells), which can repopulate at different rates. Its wider use could become a useful tool for better understanding reasons of rituximab failure or avoiding unnecessary retreatments.

26 November 2020 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
Lucia Del VecchioLucia Del Vecchio
Lucia Del Vecchio
RERobert Ekart
Robert Ekart
CFCharles J Ferro
Charles J Ferro
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
PMPatrick B Mark
Patrick B Mark
FGfor the ERA-EDTA European Renal and Cardiovascular Medicine Working (EURECA-m) Group
for the ERA-EDTA European Renal and Cardiovascular Medicine Working (EURECA-m) Group
Anaemia is a common complication of chronic kidney disease (CKD). In this setting, iron deficiency is frequent because of the combination of increased iron needs to sustain erythropoiesis with increased iron losses. Over the years, evidence has accumulated on the involvement of iron in influencing pulmonary vascular resistance, endothelial function, atherosclerosis progression and infection risk. For decades, iron therapy has been the mainstay of therapy for renal anaemia together with erythropoiesis-stimulating agents (ESAs). Despite its long-standing use, grey areas still surround the use of iron therapy in CKD. In particular, the right balance between either iron repletion with adequate therapy and the avoidance of iron overload and its possible negative effects is still a matter of debate. This is particularly true in patients having functional iron deficiency. The recent Proactive IV Iron Therapy in Haemodialysis Patients trial supports the use of intravenous (IV) iron therapy until a ferritin upper limit of 700 ng/mL is reached in haemodialysis patients on ESA therapy, with short dialysis vintage and minimal signs of inflammation. IV iron therapy has also been proven to be effective in the setting of heart failure (HF), where it improves exercise capacity and quality of life and possibly reduces the risk of HF hospitalizations and cardiovascular deaths. In this review we discuss the risks of functional iron deficiency and the possible benefits and risks of iron therapy for the cardiovascular system in the light of old and new evidence.

24 April 2024 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
Lucia Del VecchioLucia Del Vecchio
Lucia Del Vecchio
DGDomenico Girelli
Domenico Girelli
FVFrancesca Vinchi
Francesca Vinchi
Mario CozzolinoMario Cozzolino
Mario Cozzolino
SESteve Elliott
Steve Elliott
Francesco LocatelliFrancesco Locatelli
Francesco Locatelli
Iron is a fundamental element for biological life, from bacteria to humans. Iron is essential for cell function and survival, energy production and metabolism, whereas increased levels cause oxidative stress. It is also a constituent of haemoglobin and thus it is necessary for oxygen transportation through the body. Given these multiple functions, the regulation of iron metabolism is complex and tight coupled with oxygen homeostasis at tissue and cellular levels, thanks to the interaction with the hypoxia inducible factor system. In patients with chronic kidney disease (CKD), iron deficiency significantly contributes to anaemia development. This frequently overlaps with chronic inflammation, causing iron- restricted erythropoiesis. To add further complexity, metabolic hyperferritinemia may, on one hand, increase the risk for CKD and, on the other, overlaps with functional iron deficiency. Excessive intracellular iron in certain cell types during CKD can also mediate cellular death (called ferroptosis), and contribute to the pathogenesis of kidney damage, atherosclerosis and vascular calcifications. This review is aimed at broadening the perspective of iron metabolism in the setting of CKD not just as a contributor to anaemia in CKD patients, but also as an important player with an impact on cell metabolism, renal fibrosis and the cardiovascular system.